• Police seek suspects in deadly birthday party shooting
  • Lawmakers launch inquires into U.S. boat strike
  • Nov. 29, 2025, 10:07 PM EST / Updated Nov. 30, 2025,…
  • Mark Kelly says troops ‘can tell’ what orders…

Be that!

contact@bethat.ne.com

 

Be That ! Menu   ≡ ╳
  • Home
  • Travel
  • Culture
  • Lifestyle
  • Sport
  • Contact Us
  • Politics Politics
☰

Be that!

Why presidents pardon turkeys

admin - Latest News - November 26, 2025
admin
10 views 10 secs 0 Comments



NBC News’ Garrett Haake explains the history behind the Thanksgiving tradition of presidential pardons for turkeys.



Source link

TAGS:
PREVIOUS
Nov. 25, 2025, 6:39 PM ESTBy Angela YangWarning: This article includes descriptions of self-harm.After a family sued OpenAI saying their teenager used ChatGPT as his “suicide coach,” the company responded on Tuesday saying it is not liable for his death, arguing that the boy misused the chatbot.The legal response, filed in California Superior Court in San Francisco, is OpenAI’s first answer to a lawsuit that sparked widespread concern over the potential mental health harms that chatbots can pose. In August, the parents of 16-year-old Adam Raine sued OpenAI and its CEO Sam Altman, accusing the company behind ChatGPT of wrongful death, design defects and failure to warn of risks associated with the chatbot.Chat logs in the lawsuit showed that GPT-4o — a version of ChatGPT known for being especially affirming and sycophantic — actively discouraged him from seeking mental health help, offered to help him write a suicide note and even advised him on his noose setup.“To the extent that any ‘cause’ can be attributed to this tragic event,” OpenAI argued in its court filing, “Plaintiffs’ alleged injuries and harm were caused or contributed to, directly and proximately, in whole or in part, by Adam Raine’s misuse, unauthorized use, unintended use, unforeseeable use, and/or improper use of ChatGPT.”Family sues OpenAI over son’s suicide03:41The company cited several rules within its terms of use that Raine appeared to have violated: Users under 18 years old are prohibited from using ChatGPT without consent from a parent or guardian. Users are also forbidden from using ChatGPT for “suicide” or “self-harm,” and from bypassing any of ChatGPT’s protective measures or safety mitigations.When Raine shared his suicidal ideations with ChatGPT, the bot did issue multiple messages containing the suicide hotline number, according to his family’s lawsuit. But his parents said their son would easily bypass the warnings by supplying seemingly harmless reasons for his queries, including by pretending he was just “building a character.”OpenAI’s new filing in the case also highlighted the “Limitation of liability” provision in its terms of use, which has users acknowledge that their use of ChatGPT is “at your sole risk and you will not rely on output as a sole source of truth or factual information.”Jay Edelson, the Raine family’s lead counsel, wrote in an email statement that OpenAI’s response is “disturbing.”“They abjectly ignore all of the damning facts we have put forward: how GPT-4o was rushed to market without full testing. That OpenAI twice changed its Model Spec to require ChatGPT to engage in self-harm discussions. That ChatGPT counseled Adam away from telling his parents about his suicidal ideation and actively helped him plan a ‘beautiful suicide.’ And OpenAI and Sam Altman have no explanation for the last hours of Adam’s life, when ChatGPT gave him a pep talk and then offered to write a suicide note,” Edelson wrote.(The Raine family’s lawsuit claimed that OpenAI’s “Model Spec,” the technical rulebook governing ChatGPT’s behavior, had commanded GPT-4o to refuse self-harm requests and provide crisis resources, but also required the bot to “assume best intentions” and refrain from asking users to clarify their intent.)Edelson added that OpenAI instead “tries to find fault in everyone else, including, amazingly, saying that Adam himself violated its terms and conditions by engaging with ChatGPT in the very way it was programmed to act.”OpenAI’s court filing argued that the harms in this case were at least partly caused by Raine’s “failure to heed warnings, obtain help, or otherwise exercise reasonable care,” as well as the “failure of others to respond to his obvious signs of distress.” It also shared that ChatGPT provided responses directing the teenager to seek help more than 100 times before his death on April 11, but that he attempted to circumvent those guardrails.“A full reading of his chat history shows that his death, while devastating, was not caused by ChatGPT,” the filing stated. “Adam stated that for several years before he ever used ChatGPT, he exhibited multiple significant risk factors for self-harm, including, among others, recurring suicidal thoughts and ideations.”Earlier this month, seven additional lawsuits were filed against OpenAI and Altman, similarly alleging negligence, wrongful death, as well as a variety of product liability and consumer protection claims. The suits accuse OpenAI of releasing GPT-4o, the same model Raine was using, without adequate attention to safety. OpenAI has not directly responded to the additional cases.In a new blog post Tuesday, OpenAI shared that the company aims to handle such litigation with “care, transparency, and respect.” It added, however, that its response to Raine’s lawsuit included “difficult facts about Adam’s mental health and life circumstances.”“The original complaint included selective portions of his chats that require more context, which we have provided in our response,” the post stated. “We have limited the amount of sensitive evidence that we’ve publicly cited in this filing, and submitted the chat transcripts themselves to the court under seal.”The post further highlighted OpenAI’s continued attempts to add more safeguards in the months following Raine’s death, including recently introduced parental control tools and an expert council to advise the company on guardrails and model behaviors.The company’s court filing also defended its rollout of GPT-4o, stating that the model passed thorough mental health testing before release.OpenAI additionally argued that the Raine family’s claims are barred by Section 230 of the Communications Decency Act, a statute that has largely shielded tech platforms from suits that aim to hold them responsible for the content found on their platforms.But Section 230’s application to AI platforms remains uncertain, and attorneys have recently made inroads with creative legal tactics in consumer cases targeting tech companies.If you or someone you know is in crisis, call or text 988 to reach the Suicide and Crisis Lifeline or chat live at 988lifeline.org. You can also visit SpeakingOfSuicide.com/resources for additional support.Angela YangAngela Yang is a culture and trends reporter for NBC News.
NEXT
Nov. 25, 2025, 6:33 PM ESTBy Berkeley Lovelace Jr.The Centers for Medicare and Medicaid Services on Tuesday announced lower prices on 15 costly prescription drugs under Medicare, including Ozempic and Wegovy. The price cuts come through the Medicare drug price negotiation program created under the Inflation Reduction Act, which President Joe Biden signed into law in 2022. It’s different from President Donald Trump’s “most favored nation” drug pricing approach, which relies on executive orders and voluntary deals with drugmakers — not legislation. Trump recently announced such a deal with Novo Nordisk, the maker of Ozempic and Wegovy, to lower the price of the drugs in exchange for tariff relief.The Trump administration has been largely quiet about the Medicare price negotiation program.This is the second round of negotiations. Last year, the Biden administration reached deals on 10 prescription drugs, including several for heart disease and diabetes. Those price cuts are set to take effect in 2026. This latest round of price negotiations will go into effect in 2027.“President Trump directed us to stop at nothing to lower health care costs for the American people,” Health and Human Services Secretary Robert F. Kennedy Jr. said in a news release. “As we work to Make America Healthy Again, we will use every tool at our disposal to deliver affordable health care to seniors.” Drugmakers can choose not to strike deals under the negotiation program, but doing so would most likely mean withdrawing their drugs from Medicare — cutting them off from one of the nation’s largest markets. Drugmakers have challenged the program in court but so far have been unsuccessful. The negotiated prices are what Medicare will pay drugmakers for the medicines, not what patients will pay out of pocket. Those discounts will save taxpayers $12 billion, according to CMS. It’s expected to save Medicare enrollees $685 million in out-of-pocket costs in 2027. Here are the negotiated prices for the drugs, based on a 30-day supply, compared to the 2024 list price:Ozempic, Rybelsus and Wegovy, for Type 2 diabetes and weight loss: $274 negotiated price, down from the $959 list price. (Negotiated prices for higher doses of Wegovy are $385.)Trelegy Ellipta, an asthma treatment: $175, down from $654.Xtandi, for prostate cancer: $7,004, down from $13,480.Pomalyst, a chemotherapy drug: $8,650, down from $21,744.Ofev, for idiopathic pulmonary fibrosis: $6,350, down from $12,622.Ibrance, a breast cancer drug: $7,871, down from $15,741.Linzess, a chronic constipation drug: $136, down from $539.Calquence, a cancer drug: $8,600, down from $14,228.Austedo and Austedo XR, for Huntington’s disease: $4,093, down from $6,623.Breo Ellipta, a COPD drug: $67, down from $397.Xifaxan, for diarrhea and irritable bowel syndrome: $1,000, down from $2,696.Vraylar, an antipsychotic drug: $770, down from $1,376.Tradjenta, a diabetes drug: $78, down from $488. Janumet and Janumet XR, diabetes drugs: $80, down from $526.Otezla, a psoriatic arthritis drug: $1,650, down from $4,722.The 15 drugs accounted for $42.5 billion, or 15%, of total Medicare Part D spending in 2024. Medicare Part D covers medications that people take at home, as opposed to those administered in a facility, such as IV chemotherapy. “The price negotiations look very reasonable to me,” said Stacie Dusetzina, a health policy professor at Vanderbilt University in Nashville, Tennessee. “It should hopefully provide some relief for taxpayers and beneficiaries in the long run.” Dusetzina said the $274 negotiated price for Ozempic and Wegovy is higher than the $250 price in Trump’s deal. “They should’ve gotten that deal for the taxpayers and the Medicare beneficiaries,” she said.The price cuts come as many Americans say the cost of prescription drugs is unaffordable.About 1 in 5 adults say they’ve skipped filling a prescription because it was too expensive, according to a survey published in July by health policy research group KFF. About 1 in 7 say they have cut pills in half or skipped doses of medicine in the last year because of the cost. Berkeley Lovelace Jr.Berkeley Lovelace Jr. is a health and medical reporter for NBC News. He covers the Food and Drug Administration, with a special focus on Covid vaccines, prescription drug pricing and health care. He previously covered the biotech and pharmaceutical industry with CNBC.
Related Post
September 25, 2025
California jewelry store targeted in smash-and-grab
October 29, 2025
Rescuers dig through rubble after Israel strikes Gaza
November 30, 2025
People arrested during anti-ICE demonstration in NYC
September 26, 2025
Gunman who attacked NYC office building had CTE
Comments are closed.
Scroll To Top
  • Home
  • Travel
  • Culture
  • Lifestyle
  • Sport
  • Contact Us
  • Politics
© Copyright 2025 - Be That ! . All Rights Reserved